|
New era for hemophilia
care in the UAE: Pfizer
introduces first prefilled
injectable therapy
(DUBAI)
-
Pfizer announces the
launch of a new and
innovative therapy for
people living with
hemophilia in the UAE. This
marks a significant
advancement in care for
individuals affected by this
rare and serious bleeding
disorder.
Hemophilia is a rare
genetic bleeding disorder in
which the blood fails to
clot properly, leading to
prolonged bleeding that can
be either spontaneous or
occur after an injury.
Unlike traditional clotting
factor replacements,
Pfizer’s new therapy targets
the tissue factor pathway
inhibitor (TFPI), a natural
anticoagulant protein. By
inhibiting TFPI, the
treatment helps restore
balance to the body’s
clotting process, reducing
the frequency of bleeding
episodes.
This
advanced therapy is
administered once a week
through a simple injection
under the skin using a
prefilled autoinjector pen.
It is the first prefilled
injectable therapy available
in the UAE, designed to make
treatment more convenient
and accessible for patients,
while reducing the burden of
frequent infusions.
Dr. Nadine Tarcha,
Pfizer Gulf Medical
Director, said:
“The introduction of this
therapy reflects Pfizer’s
ongoing commitment to
improving the lives of
people with rare diseases.
By combining scientific
innovation with a more
convenient delivery method,
we aim to empower
individuals with hemophilia
to live with greater
confidence and improved
quality of life.”
According to the
World Federation of
Hemophilia's 2023 Annual
Global Survey, more than
32,000 people in the Eastern
Mediterranean region have
been diagnosed with
hemophilia. This represents
less than half of the
expected number of cases,
suggesting that many
individuals remain
undiagnosed or lack access
to appropriate care. These
findings emphasize the
importance of early
diagnosis and
patient-friendly treatment
options that can support
better long-term outcomes.
The introduction of this
therapy supports the UAE’s
broader healthcare vision,
which prioritizes access to
innovative treatments and
improved quality of care for
people living with complex
and rare conditions.
Patients are encouraged to
speak with their healthcare
provider to determine
whether this treatment may
be appropriate for their
condition.
PRINT
THIS ARTICLE
|
